|
ABHD11-AS1
|
Tumor Cell Invasion
|
0.050 |
Biomarker |
BEFREE |
Colony formation, transwell and wound healing assays were performed to evaluate the roles of EGFR and ABHD11-AS1 on the capacity of cell proliferation, migration, and invasion.
|
31568657 |
2019 |
|
ABHD11-AS1
|
Tumor Cell Invasion
|
0.050 |
Biomarker |
BEFREE |
Long noncoding RNA ABHD11-AS1 promote cells proliferation and invasion of colorectal cancer via regulating the miR-1254-WNT11 pathway.
|
30537177 |
2019 |
|
ABHD11-AS1
|
Tumor Cell Invasion
|
0.050 |
Biomarker |
BEFREE |
Moreover, ABHD11-AS1 enhanced the abilities of cell proliferation, migration, and invasion, inhibited apoptosis in vitro, promoted tumorigenesis in vivo via sponging miR-199a-5p and then induced SLC1A5 activation.
|
31409775 |
2019 |
|
ABHD11-AS1
|
Tumor Cell Invasion
|
0.050 |
Biomarker |
BEFREE |
LncRNA ABHD11-AS1 functions as an oncogene to promote cell proliferation and invasion in endometrial carcinoma by positively targeting cyclin D1.
|
29799152 |
2018 |
|
ABHD11-AS1
|
Tumor Cell Invasion
|
0.050 |
AlteredExpression |
BEFREE |
Loss-of-function experiments suggested that silencing of ABHD11-AS1 expression could significantly reduce the proliferation, colony formation, migration and invasion of colorectal cancer cells, and increase cell apoptosis.
|
30429229 |
2018 |
|
ABHD11-AS1
|
Neoplasm Metastasis
|
0.030 |
Biomarker |
BEFREE |
ABHD11 Antisense RNA1 (ABHD11-AS1) has recently been identified as a regulator of growth and metastasis in multiple tumors, including EOC.
|
31568657 |
2019 |
|
ABHD11-AS1
|
Neoplasm Metastasis
|
0.030 |
Biomarker |
BEFREE |
The effects of ABHD11-AS1 knockdown on the cell proliferation and metastasis were evaluated by in vitro functional assays and in vivo experiments.
|
30657221 |
2019 |
|
ABHD11-AS1
|
Neoplasm Metastasis
|
0.030 |
AlteredExpression |
BEFREE |
The clinical analysis revealed that a high level of ABHD11-AS1 expression was correlated with distant metastasis, TNM stage, and tumor differentiation.
|
30575903 |
2018 |
|
ABHD11-AS1
|
Colorectal Carcinoma
|
0.020 |
Biomarker |
BEFREE |
Thus, we demonstrated that ABHD11-AS1 promotes CRC progression through the miR-1254-WNT11 pathway, which provides a new insight into the therapeutic strategies for CRC.
|
30537177 |
2019 |
|
ABHD11-AS1
|
Neoplasms
|
0.020 |
AlteredExpression |
BEFREE |
We found that ABHD11-AS1 was remarkably overexpressed in PTC, and high expression was related to tumor size, lymph node metastasis, extrathyroidal extension and advanced TNM stage.
|
31409775 |
2019 |
|
ABHD11-AS1
|
Pancreatic carcinoma
|
0.020 |
Biomarker |
BEFREE |
Furthermore, ABHD11-AS1 had a higher area under the ROC curve (AUC) than CEA, CA199 and CA125 for early PC diagnosis, while the combination of ABHD11-AS1 and CA199 was more effective than ABHD11-AS1 alone.
|
31333792 |
2019 |
|
ABHD11-AS1
|
Papillary thyroid carcinoma
|
0.020 |
Biomarker |
BEFREE |
The molecular mechanism which contributed to the oncogenic role of ABHD11-AS1 in PTC was explored by conducting mechanism experiments.
|
30657221 |
2019 |
|
ABHD11-AS1
|
Papillary thyroid carcinoma
|
0.020 |
AlteredExpression |
BEFREE |
We found that ABHD11-AS1 was remarkably overexpressed in PTC, and high expression was related to tumor size, lymph node metastasis, extrathyroidal extension and advanced TNM stage.
|
31409775 |
2019 |
|
ABHD11-AS1
|
Malignant neoplasm of pancreas
|
0.020 |
Biomarker |
BEFREE |
Furthermore, ABHD11-AS1 had a higher area under the ROC curve (AUC) than CEA, CA199 and CA125 for early PC diagnosis, while the combination of ABHD11-AS1 and CA199 was more effective than ABHD11-AS1 alone.
|
31333792 |
2019 |
|
ABHD11-AS1
|
Malignant neoplasm of colon and/or rectum
|
0.020 |
Biomarker |
BEFREE |
Long noncoding RNA ABHD11-AS1 promote cells proliferation and invasion of colorectal cancer via regulating the miR-1254-WNT11 pathway.
|
30537177 |
2019 |
|
ABHD11-AS1
|
Colorectal Carcinoma
|
0.020 |
Biomarker |
BEFREE |
Collectively, these findings manifested that the ABHD11-AS1/miR-133a/SOX4 axis may be a cogitable and promising therapeutic target for colorectal cancer.
|
30429229 |
2018 |
|
ABHD11-AS1
|
Neoplasms
|
0.020 |
AlteredExpression |
BEFREE |
The clinical analysis revealed that a high level of ABHD11-AS1 expression was correlated with distant metastasis, TNM stage, and tumor differentiation.
|
30575903 |
2018 |
|
ABHD11-AS1
|
Pancreatic carcinoma
|
0.020 |
AlteredExpression |
BEFREE |
We found that the expression of ABHD11-AS1 was significantly increased in both PC tissues and cell lines.
|
30575903 |
2018 |
|
ABHD11-AS1
|
Malignant neoplasm of pancreas
|
0.020 |
AlteredExpression |
BEFREE |
We found that the expression of ABHD11-AS1 was significantly increased in both PC tissues and cell lines.
|
30575903 |
2018 |
|
ABHD11-AS1
|
Malignant neoplasm of colon and/or rectum
|
0.020 |
Biomarker |
BEFREE |
Collectively, these findings manifested that the ABHD11-AS1/miR-133a/SOX4 axis may be a cogitable and promising therapeutic target for colorectal cancer.
|
30429229 |
2018 |
|
ABHD11-AS1
|
Malignant Neoplasms
|
0.010 |
AlteredExpression |
BEFREE |
ABHD11-AS1 was highly expressed in the PTC samples of The Cancer Genome Atlas database.
|
30657221 |
2019 |
|
ABHD11-AS1
|
Tumor Progression
|
0.010 |
AlteredExpression |
BEFREE |
STAT3-induced upregulation of lncRNA ABHD11-AS1 promotes tumour progression in papillary thyroid carcinoma by regulating miR-1301-3p/STAT3 axis and PI3K/AKT signalling pathway.
|
30657221 |
2019 |
|
ABHD11-AS1
|
Multiple tumors
|
0.010 |
Biomarker |
BEFREE |
ABHD11 Antisense RNA1 (ABHD11-AS1) has recently been identified as a regulator of growth and metastasis in multiple tumors, including EOC.
|
31568657 |
2019 |
|
ABHD11-AS1
|
Epithelial ovarian cancer
|
0.010 |
AlteredExpression |
BEFREE |
Immunohistochemistry, western blot, and qRT-PCR analysis were used to determine the expression pattern of ABHD11-AS1 and epidermal growth factor receptor (EGFR) in both EOC tissues and cell lines, respectively.
|
31568657 |
2019 |
|
ABHD11-AS1
|
ovarian neoplasm
|
0.010 |
Biomarker |
BEFREE |
lncRNA ABHD11-AS1, regulated by the EGFR pathway, contributes to the ovarian cancer tumorigenesis by epigenetically suppressing TIMP2.
|
31568657 |
2019 |